Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY19 results · Jul–Sep 2018
Marksans Pharma reported revenue from operations of ₹269.04 crore and net profit of ₹20.57 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 269.04 | — | — | 235.25 | +14.4% |
| Other income | (0.80) | — | — | 3.23 | Turned loss |
| Total income | 268.24 | — | — | 238.49 | +12.5% |
| Profit before tax | 27.72 | — | — | 30.36 | −8.7% |
| Net profit for the period | 20.57 | — | — | 24.88 | −17.3% |
| EPS, basic (₹) | 0.48 | — | — | 0.58 | −17.2% |
| Net margin (%) | 7.6 | — | 10.6 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 114.65 | — | — | 93.14 | +23.1% |
| Other income | 2.80 | — | — | 3.22 | −13.1% |
| Total income | 117.45 | — | — | 96.36 | +21.9% |
| Profit before tax | 16.54 | — | — | 16.68 | −0.8% |
| Net profit for the period | 12.34 | — | — | 13.87 | −11.0% |
| EPS, basic (₹) | 0.30 | — | — | 0.34 | −11.8% |
| Net margin (%) | 10.8 | — | 14.9 |
Consolidated
- Filed with BSE
- 17 Nov 2018, 14:56 IST
- Board meeting
- 13 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Nov 2018, 14:56 IST
- Board meeting
- 13 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE